Navigation Links
Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO
Date:6/3/2011

QUEBEC CITY, June 3, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that Martin Driscoll has been appointed as chief executive officer.  With a solid foundation established at Asmacure, Mr. Driscoll will lead the company as it progresses its lead compound, a potential new treatment for asthma with a novel mechanism-of-action, further in clinical development.  Mr. Driscoll will be supported by the Asmacure team, including the company's founder and chief medical officer Dr. Yvon Cormier.  Dr. Luc Vachon, president and former CEO of Asmacure, will be departing the company to pursue other business ventures; however, he will remain actively involved with Mr. Driscoll and the company during a transitional period over the next few months.      

Mr. Driscoll has more than 30 years experience in the pharmaceutical industry, including senior roles in general management, commercial operations and business development for both privately held and publicly traded life science companies.  He led the commercialization of several successful therapeutic products, the direct negotiation of multiple transactions, licensing and M&A and the successful submission of multiple major product regulatory filings.  

Prior to being elected CEO of Asmacure, Mr. Driscoll was CEO and a director of Javelin Pharmaceuticals, Inc., a publicly traded company focused on the development of acute care pain products, from March 2008 until July 2010, at which point he led the successful merger of the company with Hospira, Inc.  Prior to his role with Javelin, Mr. Driscoll held senior managerial roles at Schering-Plough Corporation, ViroPharma, Inc. and Reliant Pharmaceuticals.  During his tenure at Schering-Plough, Mr. Driscoll spent a significant amount of time as general manager of Key Pharmaceuticals, the Schering unit responsible for all respiratory products marketed in the U.S.        

"Given Mr. Driscoll's extensive experience, we are confident he will successfully lead Asmacure during this exciting period as the company advances the clinical development of Asmacure's novel nicotinic receptor-based programs," said Dr. John T. Henderson, Chairman of the Board for Asmacure.  

"I'm delighted to have joined a unique development company with such novel proprietary technology that has the potential to meet significant unmet medical needs and enhance current clinical practice.  The science that has been developed by the team at Asmacure under the leadership of Drs. Vachon and Cormier is truly impressive.  I look forward to closely working with the talented Asmacure team as we lead the company through this exciting time of development and growth," said Mr. Driscoll.

Mr. Driscoll holds a B.Sc. in Communications from the University of Texas at Austin.  He has also been recently appointed as a member of the board of the Epilepsy Foundation of New Jersey and served on the Advisory Board for the American Lung Association.

About Asmacure Ltee

Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases.  The company's lead compound, ASM-024, is a novel molecular entity currently in clinical development for the treatment of asthma.  ASM-024 utilizes Asmacure's proprietary technology comprised of nicotinic acetylcholine receptor agonists and is the first nicotinic receptor agonist in the clinic for this indication.  Phase II proof-of-concept studies are ongoing to assess the anti-inflammatory, bronchodilating and bronchoprotective properties of ASM-024 administered by inhalation.  

Asmacure is a privately held company located in Quebec City, Canada.  The major investors in Asmacure include Domain Associates, Fonds Bio-Innovation and Innovatech Quebec.  For more information visit www.asmacure.com

Media Contacts:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach, amielach@tiberend.com
or
Claire Sojda, csojda@tiberend.com  


'/>"/>
SOURCE Asmacure Ltee
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
2. Omeros Appoints David A. Mann to its Board of Directors
3. RainDance Technologies Appoints Olex Vice President, System Development
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
6. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
7. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
8. RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
9. UltraShape Appoints Assaf Eyal as President & CEO
10. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
11. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... The award-winning ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... is faced with the challenge of how to continue to feed a growing nation. ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving ... marijuana products targeting the needs of consumers who are incorporating medical marijuana into ... in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... providing advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience ... application consulting, Nanoscience Analytical offers a broad range of contract analysis services ...
(Date:10/7/2017)... WALTHAM, Mass. , Oct. 6, 2017 /PRNewswire/ ... pioneering work of three scientists, Jacques Dubochet, ... whose breakthrough developments in cryo-electron microscopy ... this technology within the structural biology community. The ... Scientific. Scientists can now routinely produce highly resolved, ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
Breaking Biology News(10 mins):